Flow-chart of the inclusion of subjects.

<p>Flow-chart of the inclusion of subjects.</p

Results of the SF-36 and Minnesota living with HF questionnaire (MLHFQ).

<p>Data is presented as mean±SD. P-values refers to 2-way repeated measures ANOVA between the 2 training groups. Results of the SF-36 were scored on a 0–100 scale, in which a high score represents a better quality of life. Results of the MLHFQ were scored on a 0–105 scale, in which a low score indicates few HF-related complaints.</p><p>^† Data was available for 7 subjects in the HIT-group.</p><p>^‡ Data was available for 8 subjects in the CT-group.</p><p>Results of the SF-36 and Minnesota living with HF questionnaire (MLHFQ).</p

Brachial (BA) and superficial femoral artery (SFA) endothelium-dependent vasodilation through flow-mediated dilation (FMD), peak diameter and endothelium-independent dilation (GTN), and common carotid artery (CCA) intima-media thickness (IMT).

<p>Data is presented as mean±SD. P-values refer to 2-way repeated measures ANOVA between the 2 training groups.</p><p>^# For statistical reasons, data was analyzed with three separate tests to determine <i>time</i>, <i>group</i> and <i>time*group</i> P-values. Due to technical problems, BA GTN/FMD-GTN ratio/peak blood flow was available for 9 subjects in the HIT-group and SFA FMD was available for 8 subjects in the HIT-group. CCA IMT and IMT-to-lumen ratio were available for 8 subjects in each group. SR_AUC; shear rate area-under-the-curve. CADC; conduit artery dilating capacity.</p><p>Brachial (BA) and superficial femoral artery (SFA) endothelium-dependent vasodilation through flow-mediated dilation (FMD), peak diameter and endothelium-independent dilation (GTN), and common carotid artery (CCA) intima-media thickness (IMT).</p

Subject characteristics and cardiovascular medication.

<p>Data is presented as mean±SD. P-values refer to a 1-way ANOVA.</p><p>^† Data was unavailable for 1 subject in the CT-group and 3 subjects in the control-group.</p><p>* Significantly less females compared to the control-group.</p><p>^§Lower compared to CT-group and HIT-group.</p><p>Subject characteristics and cardiovascular medication.</p